N.E.W. Advisory Services LLC Sells 416 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

N.E.W. Advisory Services LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 10,370 shares of the biopharmaceutical company’s stock after selling 416 shares during the quarter. N.E.W. Advisory Services LLC’s holdings in Gilead Sciences were worth $958,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC grew its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. grew its position in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after purchasing an additional 5,653,075 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after buying an additional 1,793,145 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its stake in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after buying an additional 1,622,806 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $97.20 on Friday. The firm has a market capitalization of $121.14 billion, a P/E ratio of 1,080.00, a P/E/G ratio of 1.34 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock’s 50-day simple moving average is $92.28 and its two-hundred day simple moving average is $85.59. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the firm posted $2.29 earnings per share. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Truist Financial raised their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Robert W. Baird boosted their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.